Mark Jeffrey DeLong
CIK 1856078 · Chief Business & Strat Officer · last filed 2026-05-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
42
Lifetime Open-Market Net
-$4.59M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Business & Strat Officer | 0 | $41.03 | $0 | -$4.59M | 42 | 2026-05-14 |
Recent Filings · Page 2 of 5
42 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-21 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +27,273 | -$37.0K | EDGAR |
| 2025-01-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,599 | -$45.9K | EDGAR |
| 2024-08-13 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Exer (M) | +5,201 | $72.0K | EDGAR |
| 2024-03-19 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −9,913 | -$564.0K | EDGAR |
| 2024-02-13 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −597 | -$40.5K | EDGAR |
| 2024-01-31 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −367 | -$23.5K | EDGAR |
| 2024-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,384 | -$90.0K | EDGAR |
| 2024-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +15,332 | -$109.0K | EDGAR |
| 2023-10-24 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −131 | -$6.0K | EDGAR |
| 2023-02-22 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +4,839 | -$25.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.